CEU: Pulmonary hypertension update

A lot can happen in 2 years. However, for patients with pulmonary arterial hypertension (PAH), time is of the essence; progress in research and discovery cannot move quickly enough. At the beginning of 2003, The Case Manager featured an article on PAH,1 a rare disease dubbed “the other hypertension.” At that time, the latest clinical trial research results were forthcoming, with the advent of Food and Drug Administration (FDA) approval of new drugs, and promising new clinical studies were underway. Today, newer pharmaceuticals have been approved and made available, and the results of clinical research offer PAH patients new hope. What better opportunity than November, Pulmonary Hypertension Awareness Month, to take a new look at the status of this rare disease?